关注
So-Yeon Kang
So-Yeon Kang
Assistant Professor at Georgetown University
在 georgetown.edu 的电子邮件经过验证 - 首页
标题
引用次数
引用次数
年份
Adverse effects of the Medicare PSI-90 hospital penalty system on revenue-neutral hospital-acquired conditions
WV Padula, JM Black, PM Davidson, SY Kang, PJ Pronovost
Journal of Patient Safety 16 (2), e97-e102, 2020
512020
Using External Reference Pricing In Medicare Part D To Reduce Drug Price Differentials With Other Countries
SY Kang, MJ DiStefano, MP Socal, GF Anderson
Health Affairs 38 (5), 804-811, 2019
382019
Financial eligibility criteria and medication coverage for independent charity patient assistance programs
SY Kang, A Sen, G Bai, GF Anderson
Jama 322 (5), 422-429, 2019
372019
Comparative Approaches to Drug Pricing
SY Kang, G Bai, MJ DiStefano, MP Socal, F Yehia, GF Anderson
Annual Review of Public Health 41, 499-512, 2020
292020
Pharmaceutical Industry Support of US Patient Advocacy Organizations: An International Context
SY Kang, G Bai, L Karas, GF Anderson
American journal of public health 109 (4), 559-561, 2019
162019
Assessing the Added Therapeutic Benefit of Ultra-Expensive Drugs
MJ DiStefano, SY Kang, F Yehia, C Morales, GF Anderson
Value in Health, 2021
152021
Characteristics of Copayment Offsets for Prescription Drugs in the United States
AP Sen, SY Kang, E Rashidi, D Ganguli, G Anderson, GC Alexander
JAMA Internal Medicine, 2021
142021
Critical care beds with continuous lateral rotation therapy to prevent ventilator-associated pneumonia and hospital-acquired pressure injury: a cost-effectiveness analysis
SY Kang, MJ DiStefano, F Yehia, MV Koszalka, WV Padula
Journal of Patient Safety 17 (2), 149-155, 2021
102021
Pharmaceutical Industry Funding to Patient-Advocacy Organization: A Cross-National Comparison of Disclosure Codes and Regulation
L Karas, R Feldman, G Bai, SY Kang, GF Anderson
Hastings Int'l & Comp. L. Rev. 42, 453, 2019
82019
Ultra-Expensive Drugs And Medicare Part D: Spending And Beneficiary Use Up Sharply
SY Kang, D Polsky, JB Segal, GF Anderson
Health Affairs 40 (6), 1000-1005, 2021
72021
Comparison of Out-of-Pocket Spending on Ultra-Expensive Drugs in Medicare Part D vs Commercial Insurance
MJ DiStefano, SY Kang, S Parasrampuria, GF Anderson
JAMA Health Forum 4 (5), e231090-e231090, 2023
62023
Factors Associated With Manufacturer Drug Coupon Use at US Pharmacies
SY Kang, AP Sen, JF Levy, J Long, GC Alexander, GF Anderson
JAMA Health Forum 2 (8), e212123-e212123, 2021
62021
Patterns of Manufacturer Coupon Use for Prescription Drugs in the US, 2017-2019
SY Kang, A Liu, G Anderson, GC Alexander
JAMA Network Open 6 (5), e2313578-e2313578, 2023
22023
Off-Label Coverage of High-Cost Drugs by Independent Charity Patient Assistance Programs
SY Kang, MP Socal, G Bai, GF Anderson
Journal of General Internal Medicine 36 (2), 555-556, 2021
22021
Guarding Against Seven Common Threats to the Credible Estimation of COVID-19 Policy Effects
EF Drabo, SY Kang, CL Gong
American Journal of Public Health 110, 1724-1725, 2020
22020
Hospital and Physician Group Practice Participation in Prior and Next-Generation Value-Based Payment Programs
SY Kang, G Anderson
JAMA Network Open 7 (2), e240392-e240392, 2024
12024
Innovation in the United States Health-Care System’s Organization and Delivery
MJ DiStefano, SY Kang, MP Socal, GF Anderson
The School of Public Policy Publications, 2022
12022
Association of Hospitals' Experience with Bundled Payment for Care Improvement Model with the Diffusion of Acute Hospital Care at Home
SY Kang
Health Services Research, 2024
2024
Characteristics of Prescription Drug Fills Using Pharmacy-Pharmacy Benefit Manager Discount Programs: The “GoodRx” Model
J Curran, Y Wang, SY Kang, A Xuan, G Anderson, G Bai, GC Alexander
Value in Health 27 (1), 35-42, 2024
2024
How Does out-of-Pocket Spending on Ultra-Expensive Drugs Compare between Medicare Part D Beneficiaries and the Commercially Insured Population?
M DiStefano, SY Kang, S Parasrampuria, G Anderson
2023 Annual Research Meeting, 2023
2023
系统目前无法执行此操作,请稍后再试。
文章 1–20